In response to a series of manufacturing problems among generic drug manufacturers, the government conducted an unannounced survey of drug manufacturing plants nationwide last month and found a violation in one location in Ehime prefecture.
Regarding generic drugs, multiple manufacturers such as "Nichi-Iko" and "Kobayashi Kako" have found problems that were manufactured in a process not approved by the government, and the effects of supply suspension and shipping adjustment are spreading.
In response to this, the Ministry of Health, Labor and Welfare conducted an unannounced on-site survey of 46 drug manufacturing plants nationwide last month.
As a result, "Matsuda Yakuhin Kogyo" in Matsuyama City, which makes "over-the-counter drugs" that can be purchased at pharmacies without a prescription, does not perform the necessary retests even though the raw materials have expired. It means that a violation of the Pharmaceuticals and Medical Devices Act was confirmed.
It is said that no health hazards have been confirmed so far, but the company is proceeding with the voluntary collection of the drugs pointed out, and Ehime Prefecture is considering administrative sanctions.
In addition, this inspection confirmed moderate deficiencies that were "needed to be improved", such as not conducting tests to confirm post-shipment quality at nine locations that manufacture generic drugs.
All of them have no effect on quality, but the Ministry of Health, Labor and Welfare has instructed them to improve.
Matsuda Yakuhin Kogyo Voluntarily collects 13 products such as cold medicine
Matsuda Pharmaceutical Co., Ltd., which was confirmed to have violated the Pharmaceuticals and Medical Devices Act, said that it did not carry out the necessary retests even though the raw materials had expired. We voluntarily collect 13 products in total.
The company says it has not received any reports of health hazards at this time.
On top of that, "Although it is a procedural deficiency, it is a fact that we did not comply with the manufacturing method stipulated by law, and this result caused a great deal of inconvenience to our customers and business partners. We take this seriously and will continue to put in place a system to prevent recurrence. "